The Art of the Possible

A balanced approach to healthcare reform begins with a simple, uncomfortable acknowledgment: the current system serves no one’s ideological vision well. It is neither a free market nor a government system. It is a baroque, path-dependent hybrid combining the worst features of both — the administrative complexity and cost-shifting of fragmented multi-payer with the regulatory rigidity and perverse incentives of heavy government involvement. Any serious reform must accept this reality and build on existing structures rather than fantasizing about demolition — whether the fantasy involves single-payer or a libertarian free market.

The first pillar is universal access to affordable coverage. This need not mean single-payer, but it means closing the gaps that leave millions exposed. A reasonable path combines several elements: permanent, more generous ACA marketplace subsidies capping household costs at a fixed income percentage; closing the Medicaid gap in non-expansion states through a federal fallback program; a robust public option available on the marketplaces as both competitive alternative and backstop where private competition is thin; and auto-enrollment of the uninsured in basic coverage at tax time, with ability to opt out. This achieves near-universal coverage without eliminating private insurance or forcing anyone off their current plan.

The second pillar is cost containment. The nation cannot spend 18 percent of GDP on healthcare without crowding out everything else — education, infrastructure, defense, deficit reduction. Real, enforceable, consumer-friendly price transparency would introduce genuine market discipline into a sector operating in deliberate opacity. Expanded federal drug price negotiation would bring pharmaceutical costs closer to international norms. Payment reform — shifting from fee-for-service to value-based models — would realign provider incentives. Investment in primary care and prevention would reduce downstream chronic disease costs. Administrative simplification — standardizing billing, claims, and prior authorization — would attack the estimated $350 billion spent annually on overhead, far more than any other country.

The third pillar is preserving innovation and quality. The United States genuinely leads in biomedical innovation, and reform must not kill the goose. Pharmaceutical and device companies must still earn reasonable returns on research investment. Private insurance and providers must retain their role — competition between public and private models can drive care delivery innovation. And clinical autonomy, the primacy of the doctor-patient relationship, must be defended even as the system gains needed regulation elsewhere.

The fourth pillar is honest fiscal accounting. Any expansion must be paid for — through explicit taxes, cost-containment savings, or a combination. The habit of promising benefits without identifying costs has eroded public trust. Transparent scoring, honest acknowledgment of trade-offs, and commitment to sustainability mean some of Elena’s ambitions and some of James’s aspirations must yield to arithmetic. The public deserves to know what reforms cost, who pays, and what they get.

Finally, the compromise must protect individual choice and conscience. Those satisfied with employer coverage keep it. Those preferring high-deductible HSA plans retain that option. Providers practicing outside the insurance system — direct primary care, concierge medicine — remain free to do so. Coverage decisions stay with patients and physicians, not bureaucrats. The system remains as decentralized as possible, with states retaining flexibility to experiment. Clear limits constrain government authority to mandate specific benefits or penalize individual choices.

But no compromise, however elegant on paper, survives first contact with people who believe the stakes are existential. And on healthcare, everyone does.